New $100 Million California Plant Part
of Baxter's $400 Million Global Biotech Push
Expansion, you might say, is in the blood of the Hyland Immuno Division of Baxter Healthcare - to the tune of US$400 million, in fact.
The latest expansive move for Baxter's Hyland Immuno unit -- which develops and produces therapeutic proteins to treat hemophilia, immune deficiencies and other blood-related disorders - is unfolding in Thousand Oaks, Calif. Baxter is planning a second and third manufacturing suite at the Thousand Oaks site. Together, the two expansions entail a capital investment of $100 million.
At the same time, Baxter's Hyland Immuno unit is rapidly expanding in Switzerland and Austria, reflecting the inherent growth imperative in the burgeoning biotechnology business. All told, Hyland Immuno's worldwide expansions that are either planned, under way or recently completed total a whopping $400 million in capital investment.
"This investment reflects the tremendous opportunity we see for growth in the biosciences area," said Harry M. Jansen Kraemer Jr., chairman and chief executive officer of Deerfield, Ill.-based Baxter International (www.baxter.com).
Added Thomas Glanzmann, president of Baxter's Glendale, Calif.-based Hyland Immuno business, "The significant investment in Hyland Immuno facilities positions us to maximize our broad biopharmaceutical technology platforms, and is a clear commitment to manufacturing excellence and continued regulatory compliance. "We will be able to better leverage our manufacturing capabilities and continue to deliver innovative products to patients around the world," Glanzmann added.
As with the first operation built on the site, the new Thousand Oaks facility will manufacture Baxter's recombinant Factor VIII therapy, Recombinate Antihemophilic Factor, a genetically modified clotting factor used as a therapy for people with hemophilia.
The two new Thousand Oaks manufacturing facilities will add 150 employees by 2001, bringing Baxter's total employee base at that site to approximately 500.
Baxter has already submitted its application to the U.S. Food and Drug Administration for licensing the first of the two new Thousand Oaks facilities. A similar licensing request for the first facility will be submitted to the European Union by April 30. Baxter expects to submit similar applications for licensing its third Thousand Oaks manufacturing suite in June, according to company officials. Baxter hopes to receive approvals for both suites by the end of 2000, they said.
Baxter's two newly announced expansions will add to the growing biotech cluster in the Los Angeles metro.
The company, though, was already a significant player in that growing cluster. In fact, it has another new facility under way within the city of Los Angeles. Baxter recently began construction of a new $100 million, 40,000-sq.-ft., (3,600-sq.-m.) state-of-the-art plasma processing facility that is located adjacent to its existing Hyland Immuno facility in Los Angeles.
The new site, which is expected to become operational in 2003, will improve production efficiency, company officials said. The investment will increase Baxter's employment total at the Los Angeles site by the end of 2000 from 750 to 800.
Here's a look at other major projects in Hyland Immuno's global expansion juggernaut:
©2000 Conway Data, Inc. All rights reserved. Data is from many sources and is not warranted to be accurate or current.